SYNOLIS V-A: the flexible osteoarthritis treatment

SYNOLIS V-A offers an individualised dosing schedule, to maximise benefits for each patient[4]



* Multiple injections according to conventional practice with a one-week interval between injections
** On the Kellgren-Lawrence grading scale

4. Data on file.

For all your osteoarthritis patients, choose the V-A effect

- Unique combined activities of HA and sorbitol
- Flexible dosing
- Intense, fast and prolonged pain relief

&

- Also, proven safety profile
  - Only 1.92% of SYNOLIS V-A patients experienced an adverse event [11,12]
  - The most frequent adverse event associated with SYNOLIS V-A was injection site joint pain (1.3%) [11,12]

Aptissen
Chemin des Aulx 18
1228 Plan-les-Ouates
Geneva/Switzerland
mail@aptissen.com
www.aptissen.com

Swiss Technology

aptissen

ORT-01-01EN

THE FIRST INTRA-ARTICULAR VISCO-ANTALGIC

SYNOLIS V-A is the first visco-antalgic intra-articular injection combining hyaluronic acid and sorbitol to amplify pain relief for most osteoarthritis patients regardless of disease severity.

SYNOLIS V-A
DESIGNED TO AMPLIFY PAIN RELIEF

Introducing SYNOLIS V-A: the first intra-articular visco-antalgic

Thanks to the unique combined activities of HA (2%) + sorbitol (4%), SYNOLIS V-A[1]:

- **Is highly stable**[2,3]
  Sorbitol protects HA from degradation
- **Counterbalances oxidative stress**
  Sorbitol is an anti-oxidant that neutralises free radicals
- **Offers adaptive visco-elasticity**
  SYNOLIS V-A reacts like healthy human synovial fluid when subjected to mechanical stress[2,3]

1. SYNOLIS V-A, IFU 2011.
2. Gavard S, Reymond L. OARSI 2013 - Poster # 590.
3. US Patent US 2010/0184720 A1.

The V-A Effect: intense, fast, prolonged pain relief

SYNOLIS V-A amplifies pain relief for most osteoarthritis patients, regardless of initial disease severity[5-12]

INTENSE PAIN RELIEF [5-7,9]

Pain scores were improved by 1.7 points (on a 5-point Likert scale) 6 months after injection of SYNOLIS V-A

FAST PAIN RELIEF [5-9]

Meaningful* pain relief was reported by 66% of patients 1 week after injection of SYNOLIS V-A reported independent of initial disease severity

PROLONGED PAIN RELIEF [7-9]

Meaningful* pain relief was reported by >80% of all patients 6 months after injection of SYNOLIS V-A

- 82% of patients with grade I/II OA**
- 86% of patients with grade III/IV OA**

** On the Kellgren-Lawrence grading scale

Study design[9-12]: Non-interventional study to determine the efficacy and tolerability of SYNOLIS V-A intra-articular injections. A total of 1147 patients enrolled in 398 centres were treated with a single 2mL injection (55% of patients) or 3 injections (33% of patients). The primary endpoint was pain level which was assessed using a Likert-type scale from none (0) to very severe (4).

*≥ 1 point improvement on 5-point pain scale

5. Bausani M. Poster Presentation. SIR Annual Scientific Meeting. Milan, Italy. November 21-24, 2012.
6. Conrozier T. et al., Poster Presentation. ECCEO European Congress. Valencia, Spain. March 23-26, 2011.
7. Bausani M. et al., Poster Presentation. EFORT Congress. Istanbul, Turkey. June 5-8, 2013.

SYNOLIS V-A PAIN RELIEF CURVE



8. Bausani M. Poster Presentation. 2013 OARSI World Congress. Philadelphia, USA. April 18-21, 2013.
9. Data on file.
10. Kipshoven C. Poster Presentation. EFORT Congress 2013. Istanbul, Turkey. June 5-8, 2013.
11. Heisel J, Kipshoven C. Drug Res. 2013;63:445-9.
12. Radenne F. Poster. NZIOACON Congress 2013. Srinagar, India. May 31- June 2, 2013.